Cross-institution positioning
Apr 27, 2026Mixed positioning. No institution has two comparable Schedule 13 observations yet.
Source: Schedule 13 researchINDV Institutional Ownership
Indivior Pharmaceuticals, Inc.
Latest stored close $35.83 as of Oct 9, 2026 View live quote ↗
STOCKNODE Outlook
Neutral
59/100
1 tracked · 0 comparable
Latest filing
Apr 27, 2026
Positive breadth
1 positive · 0 negative
Recent close
$35.83
Research confidence
Limited
Institutional Research 54/100 · 0 accumulating · 0 reducing / exited
Ownership history
Reported ownership % history
Latest filing Apr 27, 2026
See how each tracked institution's reported ownership changed across SEC position dates. Full history is available with Investor or Pro access.
Locked preview
Unlock the reported ownership timeline
Unlock full research
Accumulating0
Newly reported1
Reducing / exited
0
52-week position
—
Institutional Intelligence
Why STOCKNODE says Neutral
What the evidence shows across the newest institutional, insider, company-event, 13F, fundamental, and price data; STOCKNODE combines these layers into a quantitative research signal while preserving each source and reporting window.
STOCKNODE Outlook
Neutral 59/100
Confidence:Limited
Why this signal
- 0 tracked institutions accumulating versus 0 reducing/exited.
- Latest comparable Form 13F activity is net positive across tracked managers.
Institutional
61/100
Insiders
57/100
Fundamentals
58/100
Events
50/100
Quarterly 13F activity
Jun 30, 20262 increased/new, 0 reduced/exited across 2 managers in the latest comparable Form 13F quarter.
Source: Form 13F quarter-end holdingsInsider filing activity
Aug 27, 2026Over the last 90 days, SEC-coded non-derivative P/S activity includes 2 purchases by 1 reporting owner and 2 sales by 1 reporting owner. Amendments are shown in the filing evidence but excluded from rolling activity totals.
Source: SEC Forms 3/4/5Material company events
Oct 6, 20267 non-amendment material events in the last 90 days; 1 capital-related filing/event; Latest classified evidence: Other event. Registration and prospectus filings are treated as financing capacity/disclosure evidence, not proof that securities were sold.
Source: SEC 8-K / securities filing metadataSEC fundamentals
Aug 3, 2026Revenue +13.6% YoY; Net income +577.8% YoY. Periods are compared only when the SEC facts are aligned and comparable.
Source: SEC Company Facts
Latest filing decision brief
Investor / Pro
Research the latest Initial Schedule 13G from Vanguard Capital Management.
Filed Apr 27, 2026. Unlock the dated position comparison, disclosure classification, confidence, price context, and filing-specific significance analysis.
Premium research values are withheld until unlocked.
Supporting institutional evidence
Institutional Evidence
The research summary above gives the current read. This section shows the dated holder-level evidence behind it.
Latest filing
Apr 27, 2026
Latest reported position changes
Investor / Pro detailSee each institution's newest reported position against its own prior report, with position as-of date separated from SEC filed date. Institution names and filing freshness remain public below.
Vanguard Capital Management
Filed Apr 27, 2026
Direction locked
Unlock the actual direction, share change, ownership change, and classification basis.
No premium position values are sent in this locked preview.
Unlock full research
Reported direction breadth by as-of date
Locked previewComparable holder direction grouped by SEC position as-of date — never presented as trade dates.
Unlock actual accumulation vs. reduction breadth across reported position dates.
View plans
Institution comparison
Investor / Pro detailCompare each institution only with its own prior reported position. Public visitors can see who is tracked and how fresh the filing is; paid research reveals the actual comparison.
Vanguard Capital Management
Filed Apr 27, 2026
Unlock the evidence behind the score
Know who changed position, by how much, and when the SEC learned about it.
Investor and Pro reveal holder-by-holder changes, reported ownership history, dated breadth, disclosure timing, institution comparison, and filing-specific analysis without treating Schedule 13 reports as trade dates.
✓ Actual share and ownership changes
✓ Position as-of date vs. SEC filed date
✓ Deterministic direction basis
✓ Full evidence on every eligible stock
SEC Forms 3, 4 & 5
Insider activity
Reported Section 16 ownership activity. Rolling purchase/sale totals use non-derivative SEC transaction codes P and S only; amendments remain visible but are excluded from those totals.
30-day purchases11 reporting owner(s)
30-day sales00 reporting owner(s)
90-day purchase breadth1
90-day sale breadth1
View recent insider filing evidence
| Date | Reporting owner | Code | Security | Shares | Price | Ownership | Filed |
|---|---|---|---|---|---|---|---|
| Aug 27, 2026 | Anderson Woodrow D | POpen-market or private purchase | Common Stock | 1.5K | $35.69 | Direct | Aug 27, 2026 |
| Aug 5, 2026 | Anderson Woodrow D | POpen-market or private purchase | Common Stock | 1.5K | $36.28 | Direct | Aug 5, 2026 |
| Jul 10, 2026 | Heidbreder Christian | SOpen-market or private sale | Common Stock | 18.6K | $41.14 | Direct | Jul 13, 2026 |
| Jun 22, 2026 | Ciaffoni Joseph | MExercise or conversion of derivative · derivative | Performance Stock Units | 1.3M | — | Direct | Jun 23, 2026 |
| Jun 22, 2026 | Ciaffoni Joseph | FTax/price withholding or payment | Common Stock | 612.5K | $38.32 | Direct | Jun 23, 2026 |
| Jun 22, 2026 | Ciaffoni Joseph | MExercise or conversion of derivative | Common Stock | 1.3M | — | Direct | Jun 23, 2026 |
| Jun 11, 2026 | Heidbreder Christian | SOpen-market or private sale | Common Stock | 18.6K | $38.06 | Direct | Jun 12, 2026 |
| Jun 8, 2026 | Preblick Ryan | SOpen-market or private sale | Common Stock | 36.0K | $37.70 | Direct | Jun 10, 2026 |
| May 13, 2026 | Thompson Juliet | AGrant, award, or other acquisition | Common Stock | 6.5K | $0.00 | Direct | May 14, 2026 |
| May 13, 2026 | Humphreys Keith | AGrant, award, or other acquisition | Common Stock | 6.5K | $0.00 | Direct | May 14, 2026 |
| May 13, 2026 | Kingsley Stuart A | AGrant, award, or other acquisition | Common Stock | 6.5K | $0.00 | Direct | May 14, 2026 |
| May 13, 2026 | NINIVAGGI DANIEL A | AGrant, award, or other acquisition | Common Stock | 6.5K | $0.00 | Direct | May 14, 2026 |
| May 13, 2026 | Ryan Barbara | AGrant, award, or other acquisition | Common Stock | 6.5K | $0.00 | Direct | May 14, 2026 |
| May 13, 2026 | Stejbach Mark | AGrant, award, or other acquisition | Common Stock | 6.5K | $0.00 | Direct | May 14, 2026 |
| May 13, 2026 | Wheadon David E. | AGrant, award, or other acquisition | Common Stock | 10.4K | $0.00 | Direct | May 14, 2026 |
| May 12, 2026 | Thompson Juliet | FTax/price withholding or payment | Common Stock | 1.1K | $38.28 | Direct | May 14, 2026 |
SEC company-event context
Material company events
Recent 8-K item classifications plus securities registration and prospectus filings. Registration or prospectus filings show financing capacity/disclosure activity; they do not by themselves prove that securities were sold.
30-day material events4
90-day capital-related1
90-day equity-related0
90-day debt-related0
View recent company-event filing evidence
| Filed | Form | 8-K item(s) | Classification | Capital context | SEC |
|---|---|---|---|---|---|
| Oct 6, 2026 | 8-K | 8.01 | Other event | — | Filing |
| Sep 17, 2026 | 8-K | 7.01, 8.01, 9.01 | Regulation FD disclosure; Other event; Financial statements / exhibits | — | Filing |
| Sep 15, 2026 | 8-K | 1.02, 9.01 | Termination of material agreement; Financial statements / exhibits | — | Filing |
| Sep 11, 2026 | 424B3 | — | Prospectus filing | Capital-related | Filing |
| Aug 3, 2026 | 8-K | 7.01, 9.01 | Regulation FD disclosure; Financial statements / exhibits | — | Filing |
| Aug 3, 2026 | 8-K | 2.02, 7.01, 9.01 | Results of operations / financial condition; Regulation FD disclosure; Financial statements / exhibits | — | Filing |
| Aug 3, 2026 | 8-K | 1.01, 7.01, 9.01 | Material definitive agreement; Regulation FD disclosure; Financial statements / exhibits | — | Filing |
| May 15, 2026 | 8-K | 5.02, 5.07 | Director or executive change; Shareholder vote results | — | Filing |
| May 4, 2026 | 8-K | 7.01, 8.01, 9.01 | Regulation FD disclosure; Other event; Financial statements / exhibits | — | Filing |
| Apr 30, 2026 | 8-K | 2.02, 7.01, 9.01 | Results of operations / financial condition; Regulation FD disclosure; Financial statements / exhibits | — | Filing |
| Mar 17, 2026 | 8-K | 1.01, 1.02, 2.03, 3.02, 9.01 | Material definitive agreement; Termination of material agreement; New direct financial obligation; Unregistered sale of equity securities; Financial statements / exhibits | Equity | Filing |
| Mar 13, 2026 | 8-K | 8.01, 9.01 | Other event; Financial statements / exhibits | — | Filing |
SEC-reported company fundamentals
Fundamentals
Period-aligned SEC facts. Comparisons appear only when periods and units are comparable.
Revenue
$343.0M
Q2 2026
+13.6% YoY 10-Q filed Aug 3, 2026
Operating income
$160.0M
Q2 2026
+122.2% YoY 10-Q filed Aug 3, 2026
Operating margin
46.6%
Q2 2026
+22.8 pts YoY 10-Q filed Aug 3, 2026
Net income
$122.0M
Q2 2026
+577.8% YoY 10-Q filed Aug 3, 2026
Diluted EPS
$0.98
Q2 2026
+600.0% YoY 10-Q filed Aug 3, 2026
Operating cash flow
$220.0M
YTD through Jun 30, 2026
-5.6% YoY 10-Q filed Aug 3, 2026
Free cash flow
$193.0M
YTD through Jun 30, 2026
-8.5% YoY 10-Q filed Aug 3, 2026
Cash & equivalents
$222.0M
As of Jun 30, 2026
-56.5% YoY 10-Q filed Aug 3, 2026
Long-term debt
$487.0M
As of Jun 30, 2026
+49.4% YoY 10-Q filed Aug 3, 2026
Assets
$1.2B
As of Jun 30, 2026
-15.1% YoY 10-Q filed Aug 3, 2026
Liabilities
$1.4B
As of Jun 30, 2026
-15.7% YoY 10-Q filed Aug 3, 2026
Stockholders’ equity
$-208.0M
As of Jun 30, 2026
+19.1% YoY 10-Q filed Aug 3, 2026
Shares outstanding
118.0M
As of Jul 28, 2026
-5.4% YoY 10-Q filed Aug 3, 2026
View recent revenue trend
Quarterly
| Period | Revenue | YoY |
|---|---|---|
| Ended Jun 30, 2026 | $343.0M | +13.6% |
| Ended Mar 31, 2026 | $317.0M | +19.2% |
| Ended Sep 30, 2025 | $314.0M | +2.3% |
| Ended Jun 30, 2025 | $302.0M | +1.0% |
Annual
| Period | Revenue | YoY |
|---|---|---|
| Ended Dec 31, 2025 | $1.2B | +4.3% |
| Ended Dec 31, 2024 | $1.2B | +8.7% |
| Ended Dec 31, 2023 | $1.1B | +21.3% |
| Ended Dec 31, 2022 | $901.0M | — |
How to read Schedule 13 ownership changes
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
For more context, see how to read a Schedule 13G, filing date vs event date, or Schedule 13G vs Schedule 13D.
Current ownership filings and reported ownership changes are available on free access. Investor and Pro add filing-specific significance scoring, disclosure-speed analysis, confirmation/divergence signals, and alerts. The overall institutional consensus preview remains public. Compare plans.
Beneficial ownership filing history
Showing 2 of 2 filing(s)View beneficial ownership filing evidence
| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| Vanguard Capital Management CIK0002100119 | Jun 30, 2026 quarter end Aug 13, 2026 filed Form 13F quarter-end evidence | Earlier Form 13F quarter-end holding Quarter-end holding evidence; no ownership percentage or signal. | 5.5M | $35.83 | |||
| Vanguard Capital Management CIK0002100119 | Mar 31, 2026 observed Apr 27, 2026 filed · 27d Initial Schedule 13G | Initial Schedule 13G | 6.5M | 5.35% | $30.48 | $34.31 | $35.83 |
Explore more institutional activity
Related research
Compare INDV with other securities showing similar institutional activity or recent accumulation across several tracked institutions.